Background Management of patients affected by heart failure with reduced ejection fraction
(HFrEF) has deeply changed thanks to novel pharmacological therapies, such as …

Aims Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection
fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left …

Aims The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan reduces
mortality and hospitalizations in patients with heart failure and reduced ejection fraction …

Background Left ventricular (LV) remodelling is a major mechanism underlying disease
progression in patients with heart failure (HF) with reduced ejection fraction (EF). Previous …

Background: Data on the impact of sacubitril/valsartan (SV) therapy on phasic left atrial (LA)
and left ventricular (LV) strain in heart failure with reduced ejection fraction (HFrEF) are …

Aims This sub-study deriving from a multicentre Italian register [Deformation Imaging by
Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic …

Background The left ventricular global longitudinal strain (LVGLS) and left atrial reservoir
strain (LARS) are considered as sensitive and reliable markers of cardiac remodeling and …

Objective Although sacubitril/valsartan has recently shown its long-term benefits on
morbidity and mortality in symptomatic patients with chronic heart failure with reduced …

Sacubitril/valsartan reduces mortality in heart failure with reduced ejection fraction (HFrEF)
patients, partially due to cardiac reverse remodeling (RR). Little is known about the RR rate …

Aims Despite well‐established benefits of sacubitril/valsartan for cardiac reverse
remodelling and the prognosis of patients with heart failure with reduced ejection fraction …